SSY Group Limited — Earnings Release 2017

Oct 10, 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [221 x 47] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017

The Company announces the turnover and gross profit information, which has not been reviewed by its auditor, for the nine months ended 30 September 2017.

The board of directors (the “Board”) of SSY Group Limited (the “Company”) announces the information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2017 based on its management accounts which has not been reviewed by the auditor of the Company.

Majority of the Group’s sales are conducted in the PRC and are denominated in Renminbi, which depreciated by approximately 2.8% when translated into Hong Kong dollars for the nine months ended 30 September 2017 as compared with that for the same period of 2016. Nevertheless, turnover of the Group for the nine months ended 30 September 2017 increased by 24.2% as compared with the same period of 2016 to HK$2,105 million. Gross profit margin of the Group for the nine months ended 30 September 2017 was 55.1%, representing a rise of 4.4 percentage point from 50.7% for the same period of 2016.

Among the abovementioned turnover of the Group, sales of intravenous infusion solution (including the subcontracting products) for the nine months ended 30 September 2017 increased by 27.8% as compared with the same period of 2016 to HK$1,900 million. Among which, sales of non-PVC soft bag infusion solution was HK$1,049 million, representing 55.2% of the sales of intravenous infusion solution and an increase of 29.4% as compared with sales for the same period of 2016; sales of upright soft bag infusion solution was HK$251 million, representing 13.2% of the sales of intravenous infusion solution and an increase of 70.4% as compared with sales for the same period of 2016; sales of PP plastic bottle infusion solution was HK$409 million, representing 21.5% of the sales of intravenous infusion solution and an increase of 11.9% as compared with sales for the same period of 2016.

— 1 —

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chow Hing Yeung Company Secretary

Hong Kong, 10 October 2017

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —